A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G.
Chien KS, et al. Among authors: dong xq.
Leuk Res. 2024 Dec;147:107602. doi: 10.1016/j.leukres.2024.107602. Epub 2024 Oct 22.
Leuk Res. 2024.
PMID: 39461095
No abstract available.